These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 30348537)

  • 21. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
    García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
    Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
    Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
    Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
    Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis.
    Sharma BB; Rai K; Blunt H; Zhao W; Tosteson TD; Brooks GA
    Oncologist; 2021 Dec; 26(12):1008-1016. PubMed ID: 34506675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
    Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
    Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
    Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
    Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
    Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
    Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
    PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
    Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Terrazzino S; Cargnin S; Del Re M; Danesi R; Canonico PL; Genazzani AA
    Pharmacogenomics; 2013 Aug; 14(11):1255-72. PubMed ID: 23930673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.